Skin reactions to the new biologic anticancer drugs

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Targeted anticancer therapies, developed through molecular biology advances, offer new treatment options for solid tumors.
• These novel agents target specific molecules in cancer cells or their microenvironment, such as angiogenesis inhibitors.
• While generally better tolerated than traditional chemotherapy, these therapies introduce unique side effect profiles, particularly affecting the skin.

Purpose of the Study:

• To review the clinical presentation of skin side effects associated with new targeted anticancer therapies.
• To outline the management strategies for these cutaneous adverse events.
• To emphasize the importance of addressing these side effects for treatment adherence and patient quality of life.

Main Methods:

• Literature review of clinical presentations and management of cutaneous side effects.
• Analysis of side effect profiles associated with specific targeted therapy classes, including multikinase inhibitors, monoclonal antibodies, and anti-epidermal growth factor inhibitors.
• Synthesis of information on the impact of these reactions on treatment outcomes and patient well-being.

Main Results:

• Targeted therapies, particularly antiepidermal growth factor inhibitors, are linked to a range of cutaneous reactions.
• These reactions include acneiform eruptions, impaired wound healing, and hand-foot syndromes, which can be dose-limiting and affect mobility.
• The severity of these skin toxicities can significantly impact a patient's quality of life and necessitate treatment modifications.

Conclusions:

• Effective recognition, prevention, and management of skin side effects are essential for continuing targeted anticancer therapy.
• Addressing these cutaneous reactions can minimize patient distress and improve overall treatment outcomes.
• Proactive dermatological care is vital for patients undergoing treatment with novel targeted anticancer agents.